Metabolomics approach for predicting response to neoadjuvant chemotherapy for breast cancer

Molecular Oncology

Volumn 7, Issue 3, 2013, Pages 297-307

  Wei, Siwei ^a   Liu, Lingyan ^b   Zhang, Jian ^a   Bowers, Jeremiah ^a   Gowda, G A Nagana ^a   Seeger, Harald ^c   Fehm, Tanja ^c   Neubauer, Hans J ^c   Vogel, Ulrich ^c   Clare, Susan E ^d   Raftery, Daniel ^a  

^a PURDUE UNIVERSITY   (United States)

^b PURDUE UNIVERSITY   (United States)

^c UNIVERSITY OF TÜBINGEN   (Germany)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Breast cancer; Metabolomics; Neoadjuvant chemotherapy; Therapy response

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; GLUTAMINE; ISOLEUCINE; LINOLENIC ACID; THREONINE; TRASTUZUMAB;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CLINICAL ARTICLE; CLINICAL ASSESSMENT; FEMALE; HUMAN; HUMAN CELL; LIQUID CHROMATOGRAPHY; LOADING DRUG DOSE; MALE; MASS SPECTROMETRY; METABOLOMICS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL;

EID: 84878107076     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2012.10.003     Document Type: Article

References (69)

1. Al-Azawi D., Kelly G., Myers E., McDermott E.W., Hill A.D.K., Duffy M.J., Higgins N.O. CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer. BMC Cancer 2006, 6:220.
2. Asiago V.M., Alvarado L.Z., Shanaiah N., Gowda G.A.N., Owusu-Sarfo K., Ballas R.A., Raftery D. Early detection of recurrent breast cancer using metabolite profiling. Cancer Res. 2010, 70:8309-8318.
3. Baron A., Migita T., Tang D., Loda M. Fatty acid synthase: a metabolic oncogene in prostate cancer?. J. Cell. Biochem. 2004, 91:47-53.
4. Bathen T.F., Jensen L.R., Sitter B., Fjosne H.E., Halgunset J., Axelson D.E., Gribbestad I.S., Lundgren S. MR-determined metabolic phenotype of breast cancer in prediction of lymphatic spread, grade and hormone status. Breast Cancer Res. Treat. 2007, 104:181-189.
5. Bear H.D., Anderson S., Brown A., Smith R., Mamounas E.P., Fisher B., Margolese R., Theoret H., Soran A., Wickerham D.L., Wolmark N. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from national surgical adjuvant breast and bowel project protocol B-27. J. Clin. Oncol. 2003, 21:4165-4174.
6. Bear H.D., Anderson S., Smith R.E., Robidoux A., Kahlenberg M.S., Margolese R.G., Dakhil S.R., Pajon E.R., Hoehn J.L., Mamounas E.P., Geyer C.E., Julian T.B., Wolmark N. A randomized trial comparing preoperative (preop) doxorubicin/cyclophosphamide (AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast: results of NSABP B-27. Breast Cancer Res. Treat. 2004, 88:S16.
7. Boros L.G., Cascante M., Lee W.N.P. Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov. Today 2002, 7:364-372.
8. Chen Y.Z., Chen C.M., Yang B.L., Xu Q.H., Wu F., Liu F., Ye X., Meng X., Mougin B., Liu G.Y., Shen Z.Z., Shao Z.M., Wu J.O. Estrogen receptor-related genes as an important panel of predictors for breast cancer response to neoadjuvant chemotherapy. Cancer Lett. 2011, 302:63-68.
9. Cheng L.L., Chang I.W., Smith B.L., Gonzalez R.G. Evaluating human breast ductal carcinomas with high-resolution magic-angle spinning proton magnetic resonance spectroscopy. J. Magn. Reson. 1998, 135:194-202.
10. Claudino W.M., Quattrone A., Biganzolim L., Pestrin M., Bertini I., Di Leo A. Metabolomics: available results, current research projects in breast cancer, and future applications. J. Clin. Oncol. 2007, 25:2840-2846.
11. Clayton T.A., Lindon J.C., Cloarec O., Antti H., Charuel C., Hanton G., Provost J.P., Le Net J.L., Baker D., Walley R.J., Everett J.R., Nicholson J.K. Pharmaco-metabonomic phenotyping and personalized drug treatment. Nature 2006, 440:1073-1077.
12. Coles N.W., Johnstone R.M. Glutamine metabolism in Ehrlich ascites-carcinoma cells. Biochem. J. 1962, 83:284-291.
13. Eagle H. Nutrition needs of mammalian cells in tissue culture. Science 1955, 122:501-504.
14. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E.R., Wickerham D.L., Begovic M., DeCillis A., Robidoux A., Margolese R.G., Cruz A.B., Hoehn J.L., Lees A.W., Dimitrov N.V., Bear H.D. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 1998, 16:2672-2685.
15. Fuchs B.C., Bode B.P. Stressing out over survival: glutamine as an apoptotic modulator. J. Surg. Res. 2006, 131:26-40.
16. Gao H.C., Lu Q., Liu X., Cong H., Zhao L.C., Wang H.M., Lin D.H. Application of (1)H NMR-based metabonomics in the study of metabolic profiling of human hepatocellular carcinoma and liver cirrhosis. Cancer Sci. 2009, 100:782-785.
17. Georgiannos S.N., Weston P.M.T., Goode A.W. Correlation between albuminuria and positively charged amino-acids in gastrointestinal cancer. Int. Surg. 1995, 80:49-52.
18. Gianni L., Zambetti M., Clark K., Baker J., Cronin M., Wu J., Mariani G., Rodriguez J., Carcangiu M., Watson D., Valagussa P., Rouzier R., Symmans W.F., Ross J.S., Hortobagyi G.N., Pusztai L., Shak S. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J. Clin. Oncol. 2005, 23:7265-7277.
19. Giskeodegard G.F., Grinde M.T., Sitter B., Axelson D.E., Lundgren S., Fjosne H.E., Dahl S., Gribbestad I.S., Bathen T.F. Multivariate modeling and prediction of breast cancer prognostic factors using MR metabolomics. J. Proteome Res. 2010, 9:972-979.
20. Gowda G.A.N., Zhang S.C., Gu H.W., Asiago V., Shanaiah N., Raftery D. Metabolomics-based methods for early disease diagnostics. Expert Rev. Mol. Diagn. 2008, 8:617-633.
21. Griffin J.L., Kauppinen R.A. Tumour metabolomics in animal models of human cancer. J. Proteome Res. 2007, 6:498-505.
22. Guarneri V., Broglio K., Kau S.W., Cristofanilli M., Buzdar A.U., Valero V., Buchholz T., Meric F., Middleton L., Hortobagyi G.N., Gonzalez-Angulo A.M. Prognostic value of pathologic complete response after primary chemotherapy in relation to hormone receptor status and other factors. J. Clin. Oncol. 2006, 24:1037-1044.
23. Hayes D.F., Smerage J. Is there a role for circulating tumor cells in the management of breast cancer?. Clin. Cancer Res. 2008, 14:3646-3650.
24. Jain M., Nilsson R., Sharma S., Madhusudhan N., Kitami T., Souza A.L., Kafri R., Kirschner M.W., Clish C.B., Mootha V.K. Metabolite profiling identifies a key role for glycine in rapid cancer cell proliferation. Science 2012, 336:1040-1044.
25. Jones R.L., Smith I.E. Neoadjuvant treatment for early-stage breast cancer: opportunities to assess tumour response. Lancet Oncol. 2006, 7:869-874.
26. Kubota A., Meguid M.M., Hitch D.C. Amino-acid profiles correlate diagnostically with organ site in 3 kinds of malignant-tumors. Cancer 1992, 69:2343-2348.
27. Kuerer H.M., Newman L.A., Smith T.L., Ames F.C., Hunt K.K., Dhingra K., Theriault R.L., Singh G., Binkley S.M., Sneige N., Buchholz T.A., Ross M.I., McNeese M.D., Buzdar A.U., Hortobagyi G.N., Singletary S.E. Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J. Clin. Oncol. 1999, 17:460-469.
28. Kuhajda F.P. Fatty-acid synthase and human cancer: new perspectives on its role in tumor biology. Nutrition 2000, 16:202-208.
29. Kurebayashi J., Yamamoto Y., Tanaka K., Kohno N., Kurosumi M., Moriya T., Nishimura R., Ogawa Y., Taguchi T. Significance of serum carcinoembryonic antigen and CA 15-3 in monitoring advanced breast cancer patients treated with systemic therapy: a large-scale retrospective study. Breast Cancer 2003, 10:38-44.
30. Lai H.S., Lee J.C., Lee P.H., Wang S.T., Chen W.J. Plasma free amino acid profile in cancer patients. Semin. Cancer Biol. 2005, 15:267-276.
31. Lanza I.R., Zhang S.C., Ward L.E., Karakelides H., Raftery D., Nair K.S. Quantitative metabolomics by (1)H-NMR and LC-MS/MS confirms altered metabolic pathways in diabetes. PLoS One 2010, 5:e10538.
32. Lee E., Nichols P., Groshen S., Spicer D., Lee A.S. GRP78 as potential predictor for breast cancer response to adjuvant taxane therapy. Int. J. Cancer 2011, 128:726-731.
33. Lindon J.C., Holmes E., Nicholson J.K. Metabonomics and its role in drug development and disease diagnosis. Expert Rev. Mol. Diagn. 2004, 4:189-199.
34. Marshall C., Eremin J., El-Sheemy M., Eremin O., Griffiths P.A. Monitoring the response of large (> 3 cm) and locally advanced (T3-4, N0-2) breast cancer to neoadjuvant chemotherapy using Tc-99m-Sestamibi uptake. Nucl. Med. Commun. 2005, 26:9-15.
35. Neubauer H., Gall C., Vogel U., Hornung R., Wallwiener D., Solomayer E., Fehm T. Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res. 2008, 28:1797-1804.
36. Nicholson J.K., Lindon J.C., Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999, 29:1181-1189.
37. Nicholson J.K., Wilson I.D. Understanding 'global' systems biology: metabonomics and the continuum of metabolism. Nat. Rev. Drug Discov. 2003, 2:668-676.
38. Oakman C., Tenori L., Biganzoli L., Santarpia L., Cappadona S., Luchinat C., Di Leo A. Uncovering the metabolic fingerprint of breast cancer. Int. J. Biochem. Cell. Biol. 2011, 43:1010-1020.
39. Oakman C., Tenori L., Claudino W.M., Cappadona S., Nepi S., Battaglia A., Bernini P., Zafarana E., Saccenti E., Fornier M., Morris P.G., Biganzoli L., Luchinat C., Bertini I., Di Leo A. Identification of a serum-detectable metabolomic fingerprint potentially correlated with the presence of micrometastatic disease in early breast cancer patients at varying risks of disease relapse by traditional prognostic methods. Ann. Oncol. 2011, 22:1295-1301.
40. Padhani A.R., Hayes C., Assersohn L., Powles T., Makris A., Suckling J., Leach M.O., Husband J.E. Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. Radiology 2006, 239:361-374.
41. Paik S., Shak S., Tang G., Kim C., Baker J., Cronin M., Baehner F.L., Walker M.G., Watson D., Park T., Hiller W., Fisher E.R., Wickerham D.L., Bryant J., Wolmark N. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004, 351:2817-2826.
42. Pan Z.Z., Raftery D. Comparing and combining NMR spectroscopy and mass spectrometry in metabolomics. Anal. Bioanal. Chem. 2007, 387:525-527.
43. Parissenti A.M., Chapman J.A.W., Kahn H.J., Guo B.Q., Han L., O'Brien P., Clemons M.P., Jong R., Dent R., Fitzgerald B., Pritchard K.I., Shepherd L.E., Trudeau M.E. Association of low tumor RNA integrity with response to chemotherapy in breast cancer patients. Breast Cancer Res. Treat. 2010, 119:347-356.
44. Proenza A.M., Oliver J., Palou A., Roca P. Breast and lung cancer are associated with a decrease in blood cell amino acid content. J. Nutr. Biochem. 2003, 14:133-138.
45. Rouzier R., Perou C.M., Symmans W.F., Ibrahim N., Cristofanilli M., Anderson K., Hess K.R., Stec J., Ayers M., Wagner P., Morandi P., Fan C., Rabiul I., Ross J.S., Hortobagyi G.N., Pusztai L. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 2005, 11:5678-5685.
46. Sciuto R., Pasqualoni R., Bergomi S., Petrilli G., Vici P., Belli F., Botti C., Mottolese M., Maini C.L. Prognostic value of Tc-99m-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J. Nucl. Med. 2002, 43:745-751.
47. Serkova N.J., Niemann C.U. Pattern recognition and biomarker validation using quantitative H-1-NMR-based metabolomics. Expert Rev. Mol. Diagn. 2006, 6:717-731.
48. Sinn H.P., Schmid H., Junkermann H., Huober J., Leppien G., Kaufmann M., Bastert G., Otto H.F. [Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy]. Geburtshilfe Frauenheilkd 1994, 54:552-558.
49. Sitter B., Sonnewald U., Spraul M., Fjosne H.E., Gribbestad I.S. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002, 15:327-337.
50. Sitter B., Lundgren S., Bathen T.F., Halgunset J., Fjosne H.E., Gribbestad I.S. Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue with clinical parameters. NMR Biomed. 2006, 19:30-40.
51. Slupsky C.M., Steed H., Wells T.H., Dabbs K., Schepansky A., Capstick V., Faught W., Sawyer M.B. Urine metabolite analysis offers potential early diagnosis of ovarian and breast cancers. Clin. Cancer Res. 2010, 16:5835-5841.
52. Spratlin J.L., Serkova N.J., Eckhardt S.G. Clinical applications of metabolomics in oncology: a review. Clin. Cancer Res. 2009, 15:431-440.
53. Sreekumar A., Poisson L.M., Rajendiran T.M., Khan A.P., Cao Q., Yu J.D., Laxman B., Mehra R., Lonigro R.J., Li Y., Nyati M.K., Ahsan A., Kalyana-Sundaram S., Han B., Cao X.H., Byun J., Omenn G.S., Ghosh D., Pennathur S., Alexander D.C., Berger A., Shuster J.R., Wei J.T., Varambally S., Beecher C., Chinnaiyan A.M. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009, 457:910-914.
54. Thuerigen O., Schneeweiss A., Toedt G., Warnat P., Hahn M., Kramer H., Brors B., Rudlowski C., Benner A., Schuetz F., Tews B., Eils R., Sinn H.P., Sohn C., Lichter P. Gene expression signature predicting pathologic complete response with gemcitabine, epirubicin, and docetaxel in primary breast cancer. J. Clin. Oncol. 2006, 24:1839-1845.
55. van't Veer L.J., Dai H.Y., van de Vijver M.J., He Y.D.D., Hart A.A.M., Mao M., Peterse H.L., van der Kooy K., Marton M.J., Witteveen A.T., Schreiber G.J., Kerkhoven R.M., Roberts C., Linsley P.S., Bernards R., Friend S.H. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536.
56. Van Poznak C., Tan L., Panageas K.S., Arroyo C.D., Hudis C., Norton L., Seidman A.D. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J. Clin. Oncol. 2002, 20:2319-2326.
57. Wang L.B., Jiang Z.N., Sui M.H., Shen J.G., Xu C.Y., Fan W.M. The potential biomarkers in predicting pathologic response of breast cancer to three different chemotherapy regimens: a case control study. BMC Cancer 2009, 9:226.
58. Watanabe A., Higashi T., Sakata T., Nagashima H. Serum amino-acid levels in patients with hepatocellular-carcinoma. Cancer 1984, 54:1875-1882.
59. Weljie A.M., Bondareva A., Zang P., Jirik F.R. H-1 NMR metabolomics identification of markers of hypoxia-induced metabolic shifts in a breast cancer model system. J. Biomol. NMR 2011, 49:185-193.
60. Wise D.R., DeBerardinis R.J., Mancuso A., Sayed N., Zhang X.Y., Pfeiffer H.K., Nissim I., Daikhin E., Yudkoff M., McMahon S.B., Thompson C.B. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc. Natl. Acad. Sci. U.S.A 2008, 105:18782-18787.
61. Wise D.R., Thompson C.B. Glutamine addiction: a new therapeutic target in cancer. Trends Biochem. Sci. 2010, 35:427-433.
62. 1H NMR metabonomics to breast cancer characterization and detection. Prog. NMR Spectroc. 2005, 47:165-174.
63. Wolmark N., Wang J., Mamounas E., Bryant J., Fisher B. Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J. Natl. Cancer Inst. Monogr. 2001, 96-102.
64. Yang C., Richardson A.D., Smith J.W., Osterman A. Comparative metabolomics of breast cancer. Pac. Symp. Biocomput. 2007, 181-192.
65. Yuneva M., Zamboni N., Oefner P., Sachidanandam R., Lazebnik Y. Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells. J. Cell. Biol. 2007, 178:93-105.
66. Zeng L., Biernacka K.M., Holly J.M.P., Jarrett C., Morrison A.A., Morgan A., Winters Z.E., Foulstone E.J., Shield J.P., Perks C.M. Hyperglycaemia confers resistance to chemotherapy on breast cancer cells: the role of fatty acid synthase. Endocr. Relat. Canc. 2010, 17:539-551.
67. Zhang J., Bowers J., Liu L., Wei S., Gowda G.A., Hammoud Z., Raftery D. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One 2012, 7:e30181.
68. Zhang J., Liu L., Wei S., Gowda G.A.N., Hammoud Z., Kesler K.A., Raftery D. Metabolomics study of esophageal adenocarcinoma. J. Thorac. Cardiovasc. Surg. 2011, 141:469-475.
69. Zhang S., Gowda G.A.N., Asiago V., Shanaiah N., Barbas C., Raftery D. Correlative and quantitative H-1 NMR-based metabolomics reveals specific metabolic pathway disturbances in diabetic rats. Anal. Biochem. 2008, 383:76-84.